Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19194419 | 1.00 | CYP3A4 (0.77) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL19393775 | 0.94 | CYP3A4 (0.68) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL12227035 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL20110443 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL12572433 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL20110436 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL20110448 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL19889781 | 0.91 | CYP3A4 (0.72) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL19889767 | 0.91 | CYP3A4 (0.72) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| SCHEMBL12572430 | 0.90 | CYP3A4 (0.82) | CYP3A4CYP2C9P2RY2P2RY4POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650014-B1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2021-10-06 | — | — | EP | disclosed |